ATI-501 BID

Phase 2Small molecule

AAclaris Therapeutics, Inc.

ATI-501 BID is one of 6 small molecule programs targeting Alopecia Totalis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alopecia TotalisActive, not recruiting

Alopecia TotalisPhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Alopecia Totalis

#DrugCompanyPhaseTrials

Plaquenil

Alnylam Pharmaceuticals

Approved

1 2

Botulinum Toxin a

GSK

Phase 3

1 3

Orencia

Bristol-Myers Squibb

Phase 2

1 4

Raptiva

Roche

Phase 2

—5

ATI-50002

AAclaris Therapeutics, Inc.

Phase 2

1 6

ATI-501 BID

AAclaris Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alopecia Totalis1 trial

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Completed·AAclaris Therapeutics, Inc.·Phase 2·NCT03594227·87 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ATI-501 BID. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATI-501 BID compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATI-501 BID. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aclaris Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAclaris Therapeutics, Inc.

ATI-501 BID

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alopecia Totalis1 trial

References

Drug Info

Quick Facts

Related News